$156 Million is the total value of BLUE JAY CAPITAL MANAGEMENT, LLC's 16 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| COO | Buy | COOPER COS INC | $14,271,000 | +18.2% | 92,690 | +3.0% | 9.13% | +124.2% |
| MJN | New | MEAD JOHNSON NUTRITION CO | $14,136,000 | – | 166,370 | +100.0% | 9.04% | – |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $14,100,000 | +24.6% | 356,510 | +78.2% | 9.02% | +136.4% |
| IONS | New | IONIS PHARMACEUTICALS INC | $12,899,000 | – | 318,490 | +100.0% | 8.25% | – |
| IART | New | INTEGRA LIFESCIENCES HLDGS C | $12,125,000 | – | 180,000 | +100.0% | 7.76% | – |
| ABMD | New | ABIOMED INC | $11,718,000 | – | 123,590 | +100.0% | 7.49% | – |
| QGEN | Buy | QIAGEN NV | $10,612,000 | +6.6% | 475,000 | +31.9% | 6.79% | +102.3% |
| STJ | Buy | ST JUDE MED INC | $10,458,000 | +11.0% | 190,140 | +24.7% | 6.69% | +110.7% |
| A | Sell | AGILENT TECHNOLOGIES INC | $9,963,000 | -16.4% | 250,000 | -12.3% | 6.37% | +58.6% |
| SHPG | Sell | SHIRE PLC | $7,761,000 | -58.9% | 45,150 | -50.9% | 4.96% | -21.9% |
| DGX | Sell | QUEST DIAGNOSTICS INC | $6,641,000 | -46.7% | 92,949 | -46.9% | 4.25% | +1.1% |
| PDCO | New | PATTERSON COMPANIES INC | $6,635,000 | – | 142,600 | +100.0% | 4.24% | – |
| MASI | Sell | MASIMO CORP | $6,425,000 | -28.0% | 153,556 | -28.6% | 4.11% | +36.6% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $6,265,000 | – | 45,000 | +100.0% | 4.01% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $6,186,000 | – | 75,000 | +100.0% | 3.96% | – |
| INCY | New | INCYTE CORP | $6,160,000 | – | 85,000 | +100.0% | 3.94% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -65,600 | -100.0% | -3.20% | – |
| DEPO | Exit | DEPOMED INC | $0 | – | -535,000 | -100.0% | -3.27% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -80,020 | -100.0% | -3.39% | – |
| CPHD | Exit | CEPHEID | $0 | – | -290,000 | -100.0% | -3.57% | – |
| WMGI | Exit | WRIGHT MED GROUP N V | $0 | – | -450,000 | -100.0% | -3.67% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -164,518 | -100.0% | -3.82% | – |
| HOLX | Exit | HOLOGIC INC | $0 | – | -325,747 | -100.0% | -4.25% | – |
| IPXL | Exit | IMPAX LABORATORIES INC | $0 | – | -295,000 | -100.0% | -4.25% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -190,000 | -100.0% | -4.32% | – |
| CERN | Exit | CERNER CORP | $0 | – | -216,339 | -100.0% | -4.39% | – |
| BXLT | Exit | BAXALTA INC | $0 | – | -385,000 | -100.0% | -5.06% | – |
| ENDP | Exit | ENDO INTL PLC | $0 | – | -255,080 | -100.0% | -5.26% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -58,161 | -100.0% | -6.01% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -252,500 | -100.0% | -6.72% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -37,000 | -100.0% | -6.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC | 8 | Q2 2017 | 7.8% |
| EDWARDS LIFESCIENCES CORP | 8 | Q2 2017 | 8.4% |
| VERTEX PHARMACEUTICALS INC | 8 | Q2 2017 | 7.1% |
| SHIRE PLC | 7 | Q4 2016 | 6.4% |
| QIAGEN NV | 7 | Q1 2017 | 7.4% |
| BIOGEN INC | 6 | Q1 2017 | 7.0% |
| COOPER COS INC | 6 | Q1 2016 | 9.1% |
| INCYTE CORP | 6 | Q2 2017 | 6.6% |
| NEUROCRINE BIOSCIENCES INC | 5 | Q2 2017 | 9.1% |
| IRONWOOD PHARMACEUTICALS INC | 5 | Q2 2017 | 7.1% |
View BLUE JAY CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-10 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 13F-HR | 2015-05-13 |
View BLUE JAY CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.